{"id":"NCT02848326","sponsor":"Allergan","briefTitle":"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","officialTitle":"A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-09-06","primaryCompletion":"2018-04-02","completion":"2018-04-23","firstPosted":"2016-07-28","resultsPosted":"2018-12-06","lastUpdate":"2018-12-06"},"enrollment":834,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Migraine, With or Without Aura"],"interventions":[{"type":"DRUG","name":"Atogepant","otherNames":["AGN-241689"]},{"type":"DRUG","name":"Placebo-matching Atogepant","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Atogepant 10 mg QD","type":"EXPERIMENTAL"},{"label":"Atogepant 30 mg QD","type":"EXPERIMENTAL"},{"label":"Atogepant 30 mg BID","type":"EXPERIMENTAL"},{"label":"Atogepant 60 mg QD","type":"EXPERIMENTAL"},{"label":"Atogepant 60 mg BID","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.","primaryOutcome":{"measure":"Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period","timeFrame":"Baseline (First 28 Days of Screening/Baseline Period) to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-2.85,"sd":0.23},{"arm":"Atogepant 10 mg QD","deltaMin":-4,"sd":0.32},{"arm":"Atogepant 30 mg QD","deltaMin":-3.76,"sd":0.23},{"arm":"Atogepant 60 mg QD","deltaMin":-3.55,"sd":0.23},{"arm":"Atogepant 30 mg BID","deltaMin":-4.23,"sd":0.35},{"arm":"Atogepant 60 mg BID","deltaMin":-4.14,"sd":0.33}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0039"},{"comp":"OG000 vs OG002","p":"0.0056"},{"comp":"OG000 vs OG003","p":"0.0325"},{"comp":"OG000 vs OG004","p":"0.0010"},{"comp":"OG000 vs OG005","p":"0.0016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":75,"countries":["United States"]},"refs":{"pmids":["39982105","39648629","38462625","32822633"],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":186},"commonTop":["Nausea","Upper respiratory tract infection","Constipation","Nasopharyngitis","Fatigue"]}}